Decoy Therapeutics Files Prospectus Related To The Resale Of Up To 2,368,868 Common Shares
-SEC Filing
Stocks · News reference
Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline
Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Decoy Therapeutics Says Preclinical Data Show Single Intranasal Dose Of DCOY-CoV Maintains Drug Levels For Up To 7 Days; Expects Clinical Trials In 2027
8-K filing — Decoy Therapeutics Inc. (DCOY)
Filed: 2026-09-23 AccNo: 0001615219-26-000019 Size: 593 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.